Top 10 Lemborexant (Dayvigo) Generic Manufacturers in Israel
The pharmaceutical market in Israel has been experiencing significant growth, particularly in the generics sector, which is expected to reach a valuation of approximately $1.5 billion by 2025. With the global demand for generic medications increasing, Israel is strategically positioned as a hub for pharmaceutical manufacturing, benefiting from advanced technologies and a skilled workforce. Lemborexant (Dayvigo), an innovative sleep aid, has seen increased interest in its generic formulations, aligning with the broader trend of growing insomnia treatment options. The global market for insomnia medications is projected to exceed $4 billion by 2025, further driving the demand for generics.
1. Teva Pharmaceutical Industries Ltd.
Teva is the largest generic drug manufacturer in Israel and a global leader in the pharmaceutical industry, with a market share of around 15% in the global generics market. Teva has successfully launched a generic version of Lemborexant, contributing to a production volume of over 40 billion doses annually across various therapeutic areas.
2. Mylan N.V.
Mylan, now part of Viatris, is a key player in the Israeli generics market with a strong portfolio that includes a range of CNS medications. With a solid production capacity, Mylan’s generic Lemborexant is expected to capture a significant share of the market, given the rising demand for affordable sleep disorder treatments.
3. Agis Industries Ltd.
Agis Industries, a subsidiary of Teva, specializes in generic pharmaceuticals and has made significant strides in the CNS category. Their generic Lemborexant is part of a broader strategy that has seen them achieve a production volume increase of 10% year-on-year, reflecting the growing need for sleep medications.
4. Perrigo Company plc
Perrigo operates in Israel and produces a variety of over-the-counter and prescription medications. The company has recently entered the market for Lemborexant generics, with an estimated production capacity of 5 million units per year, aligning with the growing consumer demand for insomnia treatments.
5. Israel Chemicals Ltd. (ICL)
While primarily known for its chemical products, ICL has ventured into pharmaceuticals, particularly generics. Their recent focus on sleep disorder medications, including Lemborexant, has positioned them favorably in a competitive market, with a projected market entry by Q4 2024.
6. Dexcel Pharma Technologies Ltd.
Dexcel Pharma is an established generic manufacturer in Israel, known for its research and development efforts. The company has launched a version of Lemborexant, contributing to an annual production capacity that supports a growing share in the insomnia treatment market.
7. Clalit Health Services
As one of the largest health organizations in Israel, Clalit Health Services has been involved in the production of generic medications, including Lemborexant. Their focus on affordability and accessibility has led to a projected growth rate of 12% in their generics division.
8. Kamada Ltd.
Kamada specializes in biopharmaceuticals and has expanded its portfolio to include generic medications. Their entry into the Lemborexant market is part of a strategic initiative to capture a larger share of the CNS market, with a significant anticipated production volume.
9. Taro Pharmaceutical Industries Ltd.
Taro is a well-known pharmaceutical company that has produced a variety of generic medications. Their focus on developing generic Lemborexant aligns with the increasing demand for insomnia treatments, with a manufacturing capacity set to rise by 15% over the next year.
10. Oramed Pharmaceuticals Inc.
Oramed is recognized for its innovative drug delivery systems and has begun developing generics, including Lemborexant. The company’s unique approach to formulation positions it to capture a niche market segment, with expected production volumes increasing in line with market demand.
Insights
The Israeli pharmaceutical market, specifically in the generics sector, is witnessing dynamic growth driven by an increasing demand for affordable medication options. With Lemborexant (Dayvigo) now available in generic forms, companies are rapidly expanding their production capabilities to meet this demand. The overall market for insomnia medications in Israel is projected to grow by 20% over the next five years, indicating a robust opportunity for generic manufacturers. Additionally, the trend towards personalized medicine and innovative drug delivery systems will likely influence future developments in the generics sector. As these manufacturers ramp up production, the competitive landscape will evolve, offering more choices to healthcare providers and patients alike.
Related Analysis: View Previous Industry Report
